Mesothelin-specific CAR-T Cell Therapy with HLA-gated Safety Mechanism Selectively Kills Tumor Cells

Leading this session, our guest speaker, Dr. Talar Tokatlian from A2 Biotherapeutics, shares information on a new dual receptor CAR T cell therapy for mesothelin-expressing solid tumors. In their recent Journal for Immunotherapy of Cancer paper, Dr. Tokatlian and colleagues describe the development of a new CAR T therapeutic with a dual-signal integrator, avoiding systemic toxicity to normal tissues by pairing a MSLN-targeted CAR with a LIR-1-based inhibitory receptor which blocks cytotoxicity in normal mesothelial cells expressing the A*02 allele.